Spondyloarthritis & psoriatic arthritis
Comparative early effectiveness across 14 psoriatic arthritis (PsA) drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
Authors' conclusion
This study confirms the rapid 3-month effectiveness of IXE on joint disease activity-as fast as TNFi and JAKi (cDAPSA), and exceeding IL-12/23i and IL-23i-along with clear benefits to skin.
Study context
- Population
- Patients with PsA prescribed advanced treatment, real-world, 6 countriesanalysed
- Participants
- 1,192 patients
- Exposure
- Ixekizumab (IXE) vs TNFi, IL-12/23i and IL-23i, Janus kinase (JAKi) and secukinumab (SEC)
- Outcome
- Early descriptive and comparative real-world effectiveness
- Follow-up
- 3 months
Methodological detailspredefined interim analysis of PRO-SPIRIT, real-world, multinational (6 countries), ad hoc analysis
- Predefined interim analysis of PRO-SPIRIT
- Real-world
- Multinational (6 countries)
- Ad hoc analysis
Main finding
As reported in the abstract
Comparative effectiveness
- IXE vs TNFi: similar improvement in clinical Disease Activity in PsA (cDAPSA) but significantly greater improvement in BSA and global assessments (physician GA, patient GA (PatGA))
- IXE vs IL-12/23i and IL-23i (pooled): significantly greater improvement in cDAPSA and PatGA
- IXE as fast as JAKi in improving joint disease activity
- Responses to SEC varied by dosage
- Interim analysis
Observational data: associations, not effects.
Further findings
MDA in patients with active psoriasis (BSA ≥3%) (ad hoc analysis)
- More patients achieved MDA with IXE than JAKi or IL-12/23i
- Ad hoc analysis
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD Open. Published 20 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →